Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Drugs In Development, 2022, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.
Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Oral Mucositis - Overview
Oral Mucositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Oral Mucositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Oral Mucositis - Companies Involved in Therapeutics Development
Allander Biotechnologies LLC
Clevexel Pharma SA
Connext Co Ltd
Destiny Pharma Plc
GlycoMira Therapeutics Inc
Lakewood-Amedex Inc
Matrix Biomed Inc
MitoImmune Therapeutics Inc
Moberg Pharma AB
Spectrum Pharmaceuticals Inc
VasoDynamics Ltd
Oral Mucositis - Drug Profiles
bupivacaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVXL-0095 - Drug Profile
Product Description
Mechanism Of Action
epinephrine - Drug Profile
Product Description
Mechanism Of Action
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KMRC-011 - Drug Profile
Product Description
Mechanism Of Action
levoleucovorin calcium - Drug Profile
Product Description
Mechanism Of Action
History of Events
MIT-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nu-3 - Drug Profile
Product Description
Mechanism Of Action
pralatrexate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Bacterial Infections and Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
suramin - Drug Profile
Product Description
Mechanism Of Action
Tempol - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oral Mucositis - Dormant Projects
Oral Mucositis - Discontinued Products
Oral Mucositis - Product Development Milestones
Featured News & Press Releases
Apr 06, 2021: MitoImmune received FDA clearance of IND application for MIT-001, a novel anti-inflammatory/anti-necrotic therapy for oral mucositis in CCRT patients with head and neck cancer
Jan 07, 2021: OncoZenge announces issue of European patent related to BupiZenge
Nov 06, 2020: Moberg Pharma intends to distribute and separately list BupiZenge (BUPI)
Dec 03, 2018: Spectrum Pharmaceuticals announces positive results from phase 2 trial evaluating use of oral Leucovorin to potentially Mitigate Mucositis in patients treated with FOLOTYN (pralatrexate)
May 02, 2018: Moberg Pharma: U.S. Patent Granted For BUPI
Sep 01, 2017: Canadian patent Granted for BUPI
Sep 01, 2017: Phase 2-results for BUPI Published
Oct 19, 2016: European Patent granted for BUPI
Jan 11, 2016: Moberg Pharma Announces Positive Phase II Data for BUPI
Jun 24, 2015: Moberg Pharma To Receive Eurostars Grant Of Eur 0.9 Million
Oct 28, 2014: First Patient Included in Phase ll Study of BUPI, a Novel Topical Formulation for Treatment of Oral Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Oral Mucositis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Oral Mucositis - Pipeline by Allander Biotechnologies LLC, 2022
Oral Mucositis - Pipeline by Clevexel Pharma SA, 2022
Oral Mucositis - Pipeline by Connext Co Ltd, 2022
Oral Mucositis - Pipeline by Destiny Pharma Plc, 2022
Oral Mucositis - Pipeline by GlycoMira Therapeutics Inc, 2022
Oral Mucositis - Pipeline by Lakewood-Amedex Inc, 2022
Oral Mucositis - Pipeline by Matrix Biomed Inc, 2022
Oral Mucositis - Pipeline by MitoImmune Therapeutics Inc, 2022
Oral Mucositis - Pipeline by Moberg Pharma AB, 2022
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, 2022
Oral Mucositis - Pipeline by VasoDynamics Ltd, 2022
Oral Mucositis - Dormant Projects, 2022
Oral Mucositis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Oral Mucositis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
